Drugs / Mifamurtide
Mifamurtide
also known as
L-MTP-PE · MEPACT · Mifamurtida · Mifamurtide sodium hydrate · Mifamurtide sodium salt monohydrate · MTP-PE · Sodium mifamurtide
Other / unclassified targets NOD2
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Mepact | — | 2009-03-06 | europa.eu ↗ |
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04062721 | Aug 2025 → Nov 2028 expected | — | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07787429 | Apr 2026 → Jul 2033 expected | osteosarcoma | Anna Raciborska | Recruiting | No outcome recorded |
| Phase 2 | NCT03643133 | Oct 2018 → Sep 2026 overdue | osteosarcoma | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02441309 | Oct 2014 → Nov 2016 | osteosarcoma | University of Oxford | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01459484 | Jun 2011 → Apr 2024 | osteosarcoma | Italian Sarcoma Group | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04571229 | — | osteosarcoma | Memorial Sloan Kettering Cancer Center | Available | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mifamurtide | “The choice of mifamurtide, the liposomal form of the smallest synthetic immunogenic derivative of the wall of mycobacteria, is justified by the need to replace BCG, used in...” NCT04062721 ↗ |
| Known as | L-MTP-PE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04571229 ↗ |
| Known as | MEPACT | “MEPACT (Mifamurtide, MTP-PE) is licensed for use in the adjuvant osteosarcoma setting” NCT02441309 ↗ |
| Known as | Mifamurtida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111100 ↗ |
| Known as | Mifamurtide sodium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111100 ↗ |
| Known as | Mifamurtide sodium salt monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111100 ↗ |
| Known as | MTP-PE | “MEPACT (Mifamurtide, MTP-PE) is licensed for use in the adjuvant osteosarcoma setting” NCT02441309 ↗ |
| Known as | Sodium mifamurtide | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111100 ↗ |
| Action | Activate | “works by stimulating the immune system to destroy cancer cells.” NCT07787429 ↗ |
| Modality | Other / unclassified | “The choice of mifamurtide, the liposomal form of the smallest synthetic immunogenic derivative of the wall of mycobacteria, is justified by the need to replace BCG, used in...” NCT04062721 ↗ |
| Route | Intravenous | “Mifamurtide 2mg/m2, IV infusion” NCT02441309 ↗ |
| Target | NOD2 | “Nucleotide-binding oligomerization domain-containing protein 2 other” CHEMBL2111100 ↗ |